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would like to point out that INSURE and 
MIST are different procedures. During IN-
SURE an endotracheal tube is placed and 
invasive ventilation is applied for a short 
period of time. Although recovery of the 
respiratory drive should be quick, com-
pletely maintaining the respiratory drive is 
less important. MIST was developed to 
prevent any artificial ventilation during 
surfactant administration. While the pa-
tient is spontaneously breathing on nonin-
vasive respiratory support, a small catheter 
is placed through the vocal cords and sur-
factant is administered. So maintaining a 
sufficient respiratory drive is a key element 
in the MIST procedure. These different 
principles could warrant different levels of 
sedation.
 According to the authors it seems inap-
propriate to reach a stage of general anes-
thesia using an opioid alone. We complete-
ly agree with this statement. The purpose of 
administering premedication before endo-
tracheal intubation, also for the INSURE 
procedure, should be to reach a level of se-
dation and analgesia enough to blunt the 
stress response, reduce the physiological 
abnormalities that can accompany this 
 Dear Sir, 
 We welcome the interest shown by 
Chollat et al.  [1] in our article on remifen-
tanil as an induction agent for the INSURE 
procedure in preterm neonates  [2] . We 
thank the authors for their critical feedback 
from their experience in the field. Based on 
our own experience and on the available 
literature, we would like to comment on 
some of these critical comments.
 The authors state that remifentanil has 
become an agent used for sedation and an-
algesia for tracheal intubation or minimal-
ly invasive surfactant therapy (MIST). 
Over the past decade several articles have 
appeared in the literature on the use of 
remifentanil for endotracheal intubation, 
either as sole medication or in combination 
with other drugs  [3–6] . Also, one article 
studied the effect of remifentanil during 
the Intubation-SURfactant-Extubation pro-
cedure  [7] . However, to the best of our 
knowledge no studies have yet appeared in 
the literature investigating the efficacy and 
safety of remifentanil during MIST.
 We studied the efficacy and safety of 
remifentanil during INSURE  [2] . In their 
comment Chollat et al.  [1] refer to the 
MIST procedure on several occasions. We 
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stress response, facilitate the procedure, 
and reduce the potential for airway injury 
 [8–13] . In order to achieve these goals, a 
certain level of sedation should be achieved. 
There is no uniform definition of sufficient 
sedation before intubation and there are no 
validated methods to measure the degree of 
sedation. The sedation score we used 
should, in our opinion, adequately reflect 
the degree of sedation necessary to achieve 
the goals of premedication before endotra-
cheal intubation. However, this score is yet 
to be validated.
 Studies that evaluated remifentanil as 
single agent before endotracheal intuba-
tion used doses ranging from 1 to 3 μg/kg 
 [3–5, 7] . Chollat et al.  [1] concluded that 
the doses used in these studies provided a 
good quality of sedation. These studies did 
indeed find no significant differences in the 
total duration of intubation time and the 
number of attempts for successful intuba-
tion between the remifentanil group and 
the control groups. Unfortunately, no dif-
ference between remifentanil and other 
combinations of drugs does not indisput-
ably indicate adequate sedation in the 
remifentanil group. It can just as well mean 
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that the sedation is as bad as in the control 
groups. All studies do not explicitly report 
on the quality of sedation.
 Several other parameters can give an in-
dication about the quality of sedation, for 
example, the number of attempts and intu-
bation conditions. In the study by Choong 
et al.  [3] using 3 μg/kg of remifentanil in 
60 s, self-reported intubation conditions 
rated by the intubator on a 7-point Likert 
scale were fair to poor in 25% of cases. Be-
sides this, 3 patients received additional 
succinylcholine for reasons other than 
chest wall rigidity. Avino et al.  [4] admin-
istered 1 μg/kg remifentanil in 60 s and in-
tubation conditions were poor in 31% of 
patients. Also, 4 patients were excluded 
from the analysis because they needed 
more than 2 intubation attempts. Although 
there could be other explanations, these 
data could also reflect an insufficient de-
gree of sedation. Only Welzing et al.  [7] , 
evaluating remifentanil during INSURE, 
reported excellent or good intubation con-
ditions in all patients. Although 29% of pa-
tients needed a second intubation attempt, 
the authors mentioned that inadequate se-
dation was never the reason for failed at-
tempts.
 Taking this into consideration, the inef-
fectiveness of remifentanil in our study 
seems to possibly be in contrast with these 
previous studies. Chollat et al.  [1] suggest 
that a short time frame to allow for drug ef-
fect could be the possible cause. As de-
scribed in the methods section of our re-
port, the sedation score was performed af-
ter remifentanil infusion and if inadequate, 
the score was repeated after 30–60 s, before 
a subsequent dose was administered. This 
leads to an interval between remifentanil 
doses of about 90–120 s, enough to allow 
for drug effect based on the known fast on-
set of action of remifentanil.
 Remifentanil has a rapid onset and end 
of action, and almost immediate recovery 
of the clinical effect after interruption of 
administration. Thus, it has a short con-
text-specific half-life with a short elimina-
tion time that is not influenced by the infu-
sion time with no cumulative effects  [14] . 
Based on these pharmacokinetic character-
istics, assuming cumulative dosing in pa-
tients receiving multiple doses seems inap-
propriate, and each dose should be ac-
counted for on its own. Even if speaking of 
cumulative dosing should be justified, the 
cumulative doses used in our study are not 
that much higher than those used in previ-
ous studies administering a single dose  [3–
5, 7] .
 Finally, we would like to briefly address 
the issue of chest wall rigidity. We defini-
tively agree with Chollat et al.  [1] that the 
incidence of chest wall rigidity in our study 
was much higher than in previous studies. 
We attribute this higher incidence com-
pletely to the fast infusion rate of remifent-
anil we used in our study, which was twice 
as fast as in previous studies. Therefore, in 
our opinion it is justified to hold on to our 
conclusion that with an infusion rate of 
30 s, remifentanil carries an unacceptable 
high risk of side effects. We do agree that 
when using slower infusion rates, remifen-
tanil seems to be much safer. We also agree 
that remifentanil might be a feasible drug 
for INSURE or MIST, if used appropriately.
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